Premium
Prolactin response to nemonapride, a new antipsychotic drug, in schizophrenic patients
Author(s) -
Otani K.,
Kondo T.,
Yasui N.,
Suzuki A.,
Furukori H.,
Kaneko S.,
Ohkubo T.,
Nagasaki T.,
Sugawara K.,
Hayashi K.
Publication year - 1997
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/(sici)1099-1077(199711/12)12:6<591::aid-hup926>3.0.co;2-u
Subject(s) - prolactin , medicine , endocrinology , antipsychotic , schizophrenia (object oriented programming) , hormone , psychiatry
The prolactin response to nemonapride, a new antipsychotic drug, was studied in 27 schizophrenic inpatients (12 males, 15 females). The daily dose of nemonapride was 18 mg/day, and the duration of treatment was 3 weeks. Plasma prolactin concentrations were measured by enzyme immunoassay. Nemonapride treatment significantly ( p <0·01) increased prolactin concentrations at each week in both genders. The Δprolactin (the mean concentration during 3 weeks minus the pretreatment concentration) was significantly ( p <0·01) greater in females (mean± SD, 81·6±57·8 ng/ml) than males (34·9±19·8 ng/ml). The present study thus shows that nemonapride treatment markedly increases prolactin concentrations in schizophrenic patients, with greater responses in females than males, suggesting a strong D2 receptor blockade property of the drug. © 1997 John Wiley & Sons, Ltd.